Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson's disease symptoms by regulating brain amyloid β1-42 level

被引:16
作者
Ba, Fang [1 ]
Zhou, Yuxin [1 ]
Zhou, Jie [1 ]
Chen, Xueyun [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Rehabil, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
关键词
A beta(1-42); APP; MKK7; Parkinson's disease; Repetitive transcranial magnetic stimulation; CEREBROSPINAL-FLUID BIOMARKERS; BETA-SECRETASE ACTIVITY; GAMMA-SECRETASE; MOTOR CORTEX; BACE1; TRANSCRIPTION; PRESENILIN; NICASTRIN; SIGNS;
D O I
10.1007/s11010-019-03531-w
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Repetitive transcranial magnetic stimulation (rTMS) is a technique protecting neurons against diverse neurodegenerative disorders by delivering magnetic stimuli into the brain through the intact scalp. In the current study, the protection effect of rTMS on Parkinson's disease (PD) and the associated mechanism driving the treatment were explored. The PD symptoms were induced using 6-OHDA in mice, and the effect of rTMS of two frequencies (1Hz and 10Hz) on the cognitive behaviors and neuron viability was detected. Afterwards, the level of A beta(1-42) and activity of MKK7-ERK-Fos-APP axis under the administration of rTMS were recorded as well. The intracranial injection of 6-OHDA impaired the cognitive behaviors of the mice in the test of Morris water maze as well as reducing the viability and number of neurons in PD mice. After the treatment of rTMS of both frequencies, the cognitive function of mice was improved and the neuron viability and number were restored in mice brain tissues. The administration of rTMS also increased the cerebrospinal fluid (CSF) level of A beta(1-42) in PD mice, which was accompanied by the suppressed levels of p-MKK7, p-ERK1/2, p-c-Fos, and APP. Moreover, the effect of rTMS on mice nerve system was all exerted in a frequency-dependent manner. In conclusion, the findings outlined in the current study affirmed the protection effect of rTMS against PD. The anti-PD function of rTMS was associated with the suppression of MKK7-ERK-Fos-APP axis, which subsequently resulted in the increased CSF A beta(1-42) level and decreased brain A beta(1-42) level.
引用
收藏
页码:71 / 78
页数:8
相关论文
共 39 条
  • [1] Arias-Carrion Oscar, 2008, Int Arch Med, V1, P2, DOI 10.1186/1755-7682-1-2
  • [2] Functional γ-secretase complex assembly in Golgi/trans-Golgi network:: interactions among presenilin, nicastrin, Aph1, Pen-2, and γ-secretase substrates
    Baulac, S
    LaVoie, MJ
    Kimberly, WT
    Strahle, J
    Wolfe, MS
    Selkoe, DJ
    Xia, WM
    [J]. NEUROBIOLOGY OF DISEASE, 2003, 14 (02) : 194 - 204
  • [3] Cerebrospinal fluid A42 levels and APP processing pathway genes in Parkinson's disease
    Bekris, Lynn M.
    Tsuang, Debby W.
    Peskind, Elaine R.
    Yu, Chang E.
    Montine, Thomas J.
    Zhang, Jing
    Zabetian, Cyrus P.
    Leverenz, James B.
    [J]. MOVEMENT DISORDERS, 2015, 30 (07) : 936 - 944
  • [4] Nigral pathology and parkinsonian signs in elders without Parkinson disease
    Buchman, Aron S.
    Shulman, Joshua M.
    Nag, Sukriti
    Leurgans, Sue E.
    Arnold, Steven E.
    Morris, Martha C.
    Schneider, Julie A.
    Bennett, David A.
    [J]. ANNALS OF NEUROLOGY, 2012, 71 (02) : 258 - 266
  • [5] Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation
    Chen, R
    Classen, J
    Gerloff, C
    Celnik, P
    Wassermann, EM
    Hallett, M
    Cohen, LG
    [J]. NEUROLOGY, 1997, 48 (05) : 1398 - 1403
  • [6] Soluble βamyloid1-42: a critical player in producing behavioural and biochemical changes evoking depressive-related state?
    Colaianna, M.
    Tucci, P.
    Zotti, M.
    Morgese, M. G.
    Schiavone, S.
    Govoni, S.
    Cuomo, V.
    Trabace, L.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (08) : 1704 - 1715
  • [7] α-secretase ADAM10 as well as αAPPs is reduced in platelets and CSF of Alzheimer disease patients
    Colciaghi, F
    Borroni, B
    Pastorino, L
    Marcello, E
    Zimmermann, M
    Cattabeni, F
    Padovani, A
    Di Luca, M
    [J]. MOLECULAR MEDICINE, 2002, 8 (02) : 67 - 74
  • [8] Part-time α-secretases:: The functional biology of ADAM 9, 10 and 17
    Deuss, Miriam
    Reiss, Karina
    Hartmann, Dieter
    [J]. CURRENT ALZHEIMER RESEARCH, 2008, 5 (02) : 187 - 201
  • [9] Incidence and remaining lifetime risk of Parkinson disease in advanced age
    Driver, Jane A.
    Logroscino, Giancarlo
    Gaziano, J. Michael
    Kurth, Tobias
    [J]. NEUROLOGY, 2009, 72 (05) : 432 - 438
  • [10] Revising the definition of Alzheimer's disease: a new lexicon
    Dubois, Bruno
    Feldman, Howard H.
    Jacova, Claudia
    Cummings, Jeffrey L.
    DeKosky, Steven T.
    Barberger-Gateau, Pascale
    Delacourte, Andre
    Frisoni, Giovanni
    Fox, Nick C.
    Galasko, Douglas
    Gauthier, Serge
    Hampel, Harald
    Jicha, Gregory A.
    Meguro, Kenichi
    O'Brien, John
    Pasquier, Florence
    Robert, Philippe
    Rossor, Martin
    Salloway, Steven
    Sarazin, Marie
    de Souza, Leonardo C.
    Stern, Yaakov
    Visser, Pieter J.
    Scheltens, Philip
    [J]. LANCET NEUROLOGY, 2010, 9 (11) : 1118 - 1127